Chiasma to Participate in AACE and ECE 2016 Conferences
23 mai 2016 08h00 HE
|
Chiasma, Inc.
Publishes New Data Regarding Time-Weighted Average Response Rate from Initial Phase 3 Trial Presents New Injectable Somatostatin Analog Patient Reported Outcome Data Highlights Recently...
Chiasma Reports First Quarter 2016 Results
11 mai 2016 16h01 HE
|
Chiasma, Inc.
WALTHAM, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company developing an investigational new drug, Mycapssa™ (octreotide) capsules, for the potential...
Chiasma to Report First Quarter 2016 Financial Results on May 11, 2016
03 mai 2016 08h00 HE
|
Chiasma, Inc.
WALTHAM, Mass., May 03, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company developing an investigational new drug, octreotide capsules, for the maintenance treatment...
Chiasma to Participate in Acromegaly Community Conference
29 avr. 2016 08h00 HE
|
Chiasma, Inc.
WALTHAM, Mass., April 29, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company developing an investigational new drug, octreotide capsules, for the maintenance...
Chiasma Provides Update Regarding FDA’s Complete Response Letter for Mycapssa™ New Drug Application
18 avr. 2016 06h00 HE
|
Chiasma, Inc.
WALTHAM, Mass., April 18, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today...
FDA Issues Complete Response Letter for Mycapssa™ New Drug Application
15 avr. 2016 18h26 HE
|
Chiasma, Inc.
WALTHAM, Mass., April 15, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Upcoming Events at ENDO 2016
31 mars 2016 08h00 HE
|
Chiasma, Inc.
WALTHAM, Mass., April 14, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide) capsules, an investigational new oral drug...
Chiasma Reports Fourth Quarter and Year End 2015 Results
14 mars 2016 16h01 HE
|
Chiasma, Inc.
Initiates Pivotal EU Phase 3 Trial Expands Organization in Advance of PDUFA Date Provides Operating Expense Guidance for 2016 NEWTON, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc....
Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly
14 mars 2016 08h00 HE
|
Chiasma, Inc.
Seeks to Demonstrate Non-Inferiority of Mycapssa™ to Monthly Injections Approximately 150 Patients Targeted for Enrollment NEWTON, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc.,...
Chiasma Joins Patient Organizations Worldwide in Support of Rare Disease Day
29 févr. 2016 08h00 HE
|
Chiasma, Inc.
NEWTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company, today announced its support for Rare Disease Day 2016. In honor of Rare...